Background: The clinical significance of pyrimidine nucleoside phosphorylase (PyNPase) activity in breast carcinomas has never been determined.
Introduction

Materials and methods
In a previous study, thymidine phosphorylase (PyNPase) was recognized as an angiogenic factor which is identical to the platelet-derived endothelial cell growth factor (PD-ECGF) [1] . The angiogenic activity of PyNPase in human carcinomas indicated that the PyNPase may be involved in the progression of human carcinomas by hemorrhagic metastasis. In human colorectal carcinoma, a significant correlation was observed between neovascularization and PyNPase expression by immunohistochemical analysis [2, 3] . Previous studies in breast carcinoma also showed that PyNPase played a significant role in angiogenesis [4, 5] . However, in a few studies PyNPase expression was seen to be significantly correlated with lymph node metastasis [6, 7] , but the extent of the influence of PyNPase on the metastatic process in human carcinoma has remained unknown. The goal of our study was to determine the sequential status of PyNPase from the expression of mRNA to enzymatic activity and/or localization of PyNPase expression in human breast carcinoma. A second aim of this study was to clarify whether the mRNA level determined by reverse transcribed-polymerase chain reaction (RT-PCR) can be used in the analysis instead of enzyme activity, since the RT-PCR assay requires a much smaller amount of sample than the enzyme activity test.
Clinical samples and preparation for assays
Immediately after removal, the breast carcinoma tissue specimen was separated into three unequal batches. One-fourth of the specimen was ground into powder in liquid nitrogen for transfer into a guanidinium isothiocyanate solution to maintain the stability of mRNA, and stored at -80 °C until use. We checked RNA for degradation by loading 2 micrograms of RNA onto 1% agarose-formaldehyde gels and staining with ethidium bromide to check for intact 18S and 28S RNAs. Another 1/4 was used for immunohistochemical study with monoclonal antibody against thymidine phosphorylase (Roche, Japan); the staining procedure has been described previously [8, 9] . The remaining half of the carcinoma tissue, more than 500 mg, was assayed for enzyme activity by high performance liquid chromatography (HPLC) as described by Eda et al. [10] .
cDNA preparation from MCF7 and clinical samples MCF7, as the representative breast carcinoma cell line, was used as a control for the quantification of mRNA expression in clinical cases. The mRNA was isolated from MCF7 and from clinical samples by the guanidinium isothiocyanate extraction method as described previously [II] . The extracted mRNA was reverse transcribed into the complementary DNA (cDNA) as described by Wang et al. [12] .
Oligonucleotide primers of PyNPase and GAPDH
The upper and lower primer sequences of PyNPase used were 5'-CTA-AGC-ACC-GAC-CTC-AAG-TTG-3 1 and 5'GAG-AGC-CCT-CTG- expression ratio of PyNPase mRNA 
Statistical analysis
The relationship between the clinicopathologic features and the enzymatic activity or the expression of PyNPase mRNA were examined by Fisher's exact test. The relationship between the enzyme activity and the level of mRNA expression was analyzed by linear regression analysis. A logistic analysis was performed to determine the role of the level of PyNPase mRNA expression as an independent factor associated with lymph node metastatisation. CCT-CAT-AGT-3', respectively. These primers amplified a 464 bp fragment of the PyNPase cDNA [13] . An amplified 450 bp fragment of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) cDNA was used as an internal control [14] .
Polymerase chain reaction with endlabeled primers
We previously published the optimal conditions for the amplification of PyNPase cDNA, and have applied them in the present study [15] . The PCR conditions for GAPDH were also described previously [14] . The expression level of PyNPase mRNA was determined by comparison with the expression of PyNPase mRNA in MCF7, a control cell line. The amplified product from both clinical samples and MCF7 were electrophoresed simultaneously in an agarose gel to be evaluated under the same conditions. The expression levels were quantified with the help of a Fuji Image Analyzer (BAS1000, Fuji Photo Film Ltd., Japan).
Results
PyNPase activity and clinicopathologic features
The average PyNPase activity as determined by HPLC was 190 units/mg protein ranging from 19.5 units/mg protein to 493 units/mg protein. Thirteen cases exhibited the higher PyNPase activity of more than 190 units/mg protein, and the remaining 28 cases revealed the lower activity of less than average. Table 1 shows the relationship between the level of enzyme activity of PyNPase and clinicopathologic features. There were significant correlations between enzyme activity and vascular permeation (P = 0.02) or lymph node metastasis (P = 0.02). In addition, cases with lymph vessel permeation had higher PyNPase activity, although non-significant.
Expression of PyNPase mRNA
All examined cases expressed PyNPase mRNA in the tumor tissue. The average expression ratio of PyNPase mRNA was 1.1 ranging from 6.4 to 0.05. Like the enzyme activity, the expression of PyNPase mRNA was significantly correlated with lymph node metastasis and vascu-lar permeation. In addition, mRNA expression correlated well with enzyme activity (r -0.74, P < 0.01, Figure 1 ). Multivariate analysis revealed that the PyNPase mRNA is the second independent factor associated with lymph node metastasis (P = 0.009) after tumor size (P = 0.004, Table 2 ).
Localization of PyNPase expression in breast carcinoma tissue
Of the 41 cases, 17 showed positive staining in the tumor stromal cells but not in the carcinoma cells, and 18 cases showed positive staining in both the tumor stromal cells and the carcinoma cells. We compared the enzyme activity between the two. The average of PyNPase activity is higher in 18 cases of staining in both tumor and carcinoma cells, however, there are no significant differences between tumor and stroma versus only stroma by Student's /-analysis. The staining in the remaining six cases was negative.
Discussion
In the present study, the elevated enzyme activity of the PyNPase was significantly related to the frequency of vascular permeation. It was, however, especially noteworthy that the elevated enzyme activity of the PyNPase was significantly related to the incidence of lymph node metastasis. In gastro-intestinal carcinomas, several studies also disclosed a significant correlation between immunohistochemical status of PyNPase and lymph node metastasis [2] [3] [4] [5] [6] 7] . Our present data indicate a possible role for PyNPase in lymph node metastasis followed by vascular permeation in the promotion of breast carcinoma. However, the cause of the absence of a link between lymph node metastasis and lymph vessel permeation requires further study and only prolonged follow up study -of a possibly larger series of patientswill determine the utility of PyNPase as a prognostic marker. In this respect, it is worthwhile mentioning that three cases with stage III disease and high PyNPase activity have died of recurrent breast cancer within one year from diagnoses.
We discovered a significant correlation between enzymatic activity and expression of mRNA of PyNPase. Thus, we can predict PyNPase activity by evaluating the mRNA level as determined by RT-PCR assay. This assay, which can be performed on a small amount of sample such as can be obtained by needle biopsy, is more useful than the enzyme assay, which requires a much larger amount of sample. In our immunohistochemical study, we found that PyNPase was expressed not only in tumor cells, but also in stromal cells, indicating that the objective evaluation of PyNPase would be difficult by the immunohistochemical method. Therefore, evaluation of PyNPase mRNA by RT-PCR can be considered the more useful method, since the material includes both tumor cells and stromal cells, and the evaluation of the results is objective. Moreover, according to the multivariate analysis, evaluation of the mRNA expression level can be an independent factor associated with lymph node metastasis. The analysis of PyNPase mRNA by an RT-PCR assay may be more useful than a direct evaluation of PyNPase activity in human breast carcinoma.
